1. Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
- Author
-
Ram N. Ganapathi, Cheryl L. Willman, Frederick R. Appelbaum, Jerald P. Radich, John E. Godwin, Eric R. Koegle, Shannon McDonough, Megan Othus, Stephen H. Petersdorf, Anjali S. Advani, Mahrukh K. Ganapathi, Andrew P. Michelson, and Alan F. List
- Subjects
Male ,lcsh:Medicine ,Cohort Studies ,0302 clinical medicine ,Immunophenotyping ,Topoisomerase II Inhibitors ,Poly-ADP-Ribose Binding Proteins ,lcsh:Science ,Cancer ,Aged, 80 and over ,0303 health sciences ,Multidisciplinary ,biology ,Cytarabine ,Middle Aged ,3. Good health ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,Cell biology ,Anthracycline ,Daunorubicin ,CD14 ,Antineoplastic Agents ,Article ,Young Adult ,03 medical and health sciences ,Myelogenous ,Antigens, CD ,medicine ,Humans ,RNA, Messenger ,Aged ,030304 developmental biology ,business.industry ,Topoisomerase ,lcsh:R ,Adult Acute Myeloid Leukemia ,medicine.disease ,DNA Topoisomerases, Type II ,biology.protein ,Cancer research ,lcsh:Q ,business - Abstract
Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α and topo IIβ. In 230 patients with non-M3 AML who received frontline ara-C/daunorubicin we determined expression of topo IIα and topo IIβ by RT-PCR and its relationship to immunophenotype (IP) and outcomes. Treatment outcomes were analyzed by logistic or Cox regression. In 211 patients, available for analysis, topo IIα expression was significantly lower than topo IIβ (P
- Published
- 2020